Loading...

Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

Print Friendly, PDF & Email

LYON, France PXL770, a novel direct AMPK activator, produced additive benefits in a NASH model when combined with other late-stage agents in development PXL770 treatment was observed to improve cardio-renal disease and adrenoleukodystrophy (ALD) / adrenomyeloneuropathy (AMN) in animal models Poxel plans to further evaluate its AMPK platform for […]